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Epithelial–mesenchymal transformation (EMT) occurs during both development and tumorigenesis. Transforming growth factor beta
(TGFh) ligands signal EMT in the atrioventricular (AV) cushion of the developing heart, a critical step in valve formation. TGFh signals
through a complex of type I and type II receptors. Several type I receptors exist although activin receptor-like kinase (ALK) 5 mediates the
majority of TGFh signaling. Here, we demonstrate that ALK2 is sufficient to induce EMT in the heart. Both ALK2 and ALK5 are expressed
throughout the heart with ALK2 expressed abundantly in endocardial cells of the outflow tract (OFT), ventricle, and AV cushion.
Misexpression of constitutively active (ca) ALK2 in non-transforming ventricular endocardial cells induced EMT, while caALK5 did not,
thus demonstrating that ALK2 activity alone is sufficient to stimulate EMT. Smad6, an inhibitor of Smad signaling downstream of ALK2, but
not ALK5, inhibited EMT in AV cushion endocardial cells. These data suggest that ALK2 activation may stimulate EMT in the AV cushion
and that Smad6 may act downstream of ALK2 to negatively regulate EMT.
D 2005 Elsevier Inc. All rights reserved.
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Transforming growth factor beta (TGFh) mediates
processes as diverse as development, wound healing, and
tumor progression (Grazul-Bilska et al., 2003; Waite and
Eng, 2003). TGFh signaling occurs through the ligand-
dependent formation of a heteromeric complex of type I and
type II receptors. Both receptors contain a serine/threonine
kinase domain. The constitutively active kinase domain of
the type II receptor phosphorylates the type I receptor in the
GS box leading to activation of the type I receptor kinase
domain. Once activated, the type I receptor phosphorylates0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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University of Minnesota, Minneapolis, MN 55455, USA.downstream signaling molecules including members of the
Smads family of transcription factors (Kretzschmar and
Massague, 1998). The type I receptor activin receptor-like
kinase (ALK) 5 mediates several TGFh-induced responses.
In the presence of TGFh, ALK5 associates with the type II
TGFh receptor (TBRII) to stimulate PAI-1 expression or
growth arrest (Bassing et al., 1994; ten Dijke et al., 1994a;
Wrana et al., 1994), establishing ALK5 as the prototypic
type I TGFh receptor.
A second type I receptor, ALK2, interacts with TBRII as
well as activin and bone morphogenetic protein (BMP) type
II receptors in the presence of their respective ligands
(Attisano et al., 1993; Ebner et al., 1993a,b, 1994b;
Yamashita et al., 1995). Despite potentially signaling
through TGFh, activin, and BMP ligands ALK2 activation
has thus far only been demonstrated downstream of BMP7
binding to activin type II receptors (Macias-Silva et al.,
1998). However, data suggest that ALK2 signals down-280 (2005) 201–210
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die early in gastrulation (Gu et al., 1999) while Bmp7 null
mice survive until soon after birth (Dudley et al., 1995;
Luo et al., 1995). ALK2 has been proposed to mediate
epithelial–mesenchymal transformation (EMT) in response
to TGFh in cultured mammary epithelial cells (Miettinen
et al., 1994). This observation suggested that TGFh
ligands may signal through ALK2 and that ALK2 may
potentially mediate EMT in other cell types. However,
efforts to confirm this observation have been unsuccessful
(Piek et al., 1999).
We used explanted chick atrioventricular (AV) cushions
as a model system to identify potential roles for ALK2 and
ALK5 during EMT. EMT in the AV cushion is a critical step
in valve formation that occurs early in heart development.
During EMT, the heart is a simple tube composed of two
concentric layers of epithelia separated by an acellular
region of extracellular matrix termed the cardiac jelly. In
both the AV cushion and outflow tract (OFT), cells from the
inner endocardial layer transform into mesenchyme and
invade the cardiac jelly where they later contribute to the
connective tissue of the valves and membranous septa of the
adult heart (Lamers et al., 1995; Sadler, 1985). During EMT,
cells first undergo an activation step in which they lose their
cell–cell contacts and change shape from polygonal
epithelial cells to elongated mesenchymal cells. Subse-
quently, these activated cells invade and migrate through the
cardiac jelly to complete the transformation process. Studies
have shown that these steps occur in AV cushions, but not
ventricles, both in situ and using an in vitro model in which
explants are placed on collagen gels (Bernanke and
Markwald, 1982). To identify potential roles for candidate
molecules in EMT, ventricular or AV cushion explants can
be used to score for gain or loss of function, respectively, as
we previously reported (Brown et al., 1999). In the AV
cushion, EMT is dependent on soluble factors derived from
the outer myocardial cell layer that reach the endocardium
prior to EMT (Krug et al., 1985). In collagen gel explants,
exogenous TGFh ligands support both the epithelial cell
activation and mesenchymal cell migration that constitute
EMT in the developing chick AV cushion (Boyer et al.,
1999; Potts and Runyan, 1989; Ramsdell and Markwald,
1997).
Prior studies in our laboratory demonstrated that ALK2
antisera, but not ALK5 antisera, inhibited EMT in the AV
cushion (Lai et al., 2000). This experiment suggested a
requirement for ALK2 during EMT, but did not address
whether ALK2 was sufficient to induce transformation.
Also, these experiments could not differentiate between the
effects of the antisera on the endocardium versus the
myocardium. To address these issues, we tested whether
the activity of ALK2 or ALK5 is sufficient to induce EMT
in ventricular endocardial cells. We demonstrate that
constitutively active (ca) ALK2, but not caALK5, stimulates
normally non-transforming ventricular endocardial cells to
undergo EMT. In AV cushion endocardial cells, over-expression of Smad6, an inhibitor of ALK2 Smad signaling,
decreased EMT consistent with a role for ALK2 and
demonstrating that EMT is Smad-dependent. These data,
together with the abundant expression of ALK2 mRNA in
the endocardium of the OFT, ventricle, and AV cushion are
consistent with a physiological role for this receptor in
mediating EMT in the heart, and perhaps other organ
systems.Materials and methods
In situ hybridization
Performed as previously described (Barnett et al., 1994)
with the substitution of 33P for 35S at N2  104 cpm/Al.
Probes were as follows: chicken ALK2 (GenBank Acces-
sion # U38622; nt 245–468) and chicken ALK5 (GenBank
Accession # D14460; nt 184–468).
Alkaline phosphatase assay
C3H10T1/2 cells were split at a density of 5  104 cells/
well in a 24-well dish. Immediately after splitting, cells were
transiently transfected with 400 ng of plasmid containing
lacZ (PVR h-Gal) using Fugene 6 transfection reagent
(Roche) and infected with adenovirus encoding either Green
Fluorescent Protein (GFP) alone, caALK2, or caALK5.
Twenty-four hours later, the medium was removed and
replaced with DMEM, 0.2% FBS and vehicle or 1 Ag/ml
BMP2 was added. After 24 h, the cells were lysed with 10
mM Tris pH 7.5, 50 mM sodium acetate, 0.2 mM EDTA,
1% Triton X-100 for 30 min at 48C. Half of the lysate was
added to 1-step PNPP soluble alkaline phosphatase substrate
(Pierce) and incubated overnight at room temperature.
Alkaline phosphatase activity was measured by reading
the A405 nm. The other half of the lysate was added to
ONPG soluble h-galactosidase substrate (Pierce) to normal-
ize the samples to h-galactosidase activity. Samples were
incubated overnight at 308C and the A405 nm was
measured.
Luciferase assays
C3H10T1/2 cells were plated into 12-well dishes at 1 
105 cells/well. Cells in each well were transiently trans-
fected with 0.8 Ag of p3TP-Lux and 8 ng of a Renilla
luciferase plasmid (Promega) for normalization. Immedi-
ately after transfection, the cells were infected with
adenovirus containing either GFP alone, caALK2, or
caALK5. Twenty-four hours after transfection, the cells
were incubated in DMEM supplemented with 0.2% FBS.
Cells were harvested 24 h later and assayed for luciferase
activity (Promega Luciferase Assay System). Total light
emission was measured during the initial 10 s of the reaction
using a Turner Designs TD-20/20 Luminometer.
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Adenoviruses were generated using the pAdEasy system
(He et al., 1998). All concentrated viruses were titered by
performing serial dilutions of the concentrated virus and
counting the number of GFP-expressing 293 cells after 18–
24 h. Both the lacZ and mouse Smad6 adenoviruses were
generated by homologous recombination in 293 cells.
These viruses do not co-express GFP and therefore were
titered using the Takara Assay (Takara Shuzo Co., Ltd.).
Viral injections and collagen gel assays
Stage 10–12 chick embryos were harvested onto What-
man paper rings and immediately injected with adenovirus
in the heart lumen. Injections were performed using 20–50
pulses, approximately 50 ms each, delivered by a
picospritzer. Fast Green Dye (Sigma) was used to monitor
injection of the virus. Immediately after injection, the
embryos were placed on egg agar and incubated at 398C.
After 24 h, ventricular or AV cushion explants were
excised from the infected hearts and placed in culture as
described previously (Brown et al., 1996). After 48 h, the
explants were fixed in 0.8% formaldehyde, 0.05% gluta-
raldehyde. GFP expression by virally infected cells was
observed on an inverted fluorescent microscope. The
phenotype of each GFP-expressing cell was determined
and scored as epithelial, activated, or transformed as
described in Results. The number of ventricular explants
examined and cells in each category were as follows:
caALK2 adenovirus (n = 59; total number of cells, 1836;
epithelial, 331; activated, 1051; transformed, 454), n =
number of explants, GFP control adenovirus (n = 54; total
number of cells, 937; epithelial, 584; activated, 223;
transformed, 130), caALK5 adenovirus (n = 71; total
number of cells, 2566; epithelial, 1752; activated, 576;
transformed, 238), GFP control adenovirus (n = 75; total
number of cells, 1359; epithelial, 827; activated, 360;
transformed, 172). The number of AV cushion explants
examined and cells in each category were as follows:
caALK5 adenovirus (n = 41; total number of cells, 2061;
epithelial, 1074; activated, 552; transformed, 435). GFP
control adenovirus (n = 35; total number of cells, 1051;
epithelial, 538; activated, 280; transformed, 233), caALK2
adenovirus (n = 48; total number of cells, 1976; epithelial,
682; activated, 743; transformed, 551). GFP control
adenovirus (n = 51; total number of cells, 3758; epithelial,
1486; activated, 1152; transformed, 1120).
AV cushion explants infected with either lacZ or Smad6
adenoviruses were scored for the total number of trans-
formed cells by optically sectioning the collagen gels using
Hoffman Optics. The number of explants in each group
and the mean number of transformed cells F SEM,
expressed as a percentage of control, were as follows:
lacZ adenovirus (n = 54; 100 F 8%), Smad6 adenovirus
(n = 48; 65 F 10%).Results
ALK2 mRNA is abundantly expressed in the endocardium
We analyzed the expression patterns of both ALK2 and
ALK5 by in situ hybridization in stage 14–19 embryonic
chicken hearts (Hamburger and Hamilton, 1951). These
embryonic stages are inclusive of the initiation of EMT in
both the AV cushion and OFT. The mRNA expression
pattern for both of these receptors was invariant throughout
the stages examined. While ALK2 mRNA expression was
noted throughout the embryo, expression was particularly
abundant in endothelial cells comprising the endocardium of
the heart (Figs. 1A, B). Expression of ALK2 was abundant
in the OFT, ventricle, and AV cushion with a decrease in
expression observed at the border between the AV cushion
and the atria (Figs. 1E, F) and between the OFT and the
beginning of the aortic sac (Figs. 1G, H). Notably, little
expression of ALK2 mRNA was observed in endothelial
cells outside of the heart such as in the dorsal aorta (Figs.
1A, B). The abundant endocardial expression of ALK2
contrasted sharply with the expression pattern of ALK5
mRNA. ALK5 is expressed at low levels throughout the
embryo, including the endocardium (Figs. 1C, D). These
studies show endocardial expression of both ALK2 and
ALK5 during EMT with notably high levels of ALK2
observed in the OFT, ventricle, and AV cushion compared to
the rest of the embryo.
Constitutively active ALK2 and ALK5 are specific for their
respective signaling pathways
The expression of both type I receptors in the heart
prompted us to address the functional role of each during
EMT. We reasoned that if ALK2 or ALK5 are sufficient to
stimulate EMT in the heart, then the misexpression of
constitutively active forms of these receptors in ventricular
endocardial cells, which do not normally undergo EMT,
should result in a gain of function. In mammalian type I
receptors, single amino acid substitutions for an aspartate
residue in a region known as the GS box have previously
been demonstrated to render these receptors constitutively
active (Macias-Silva et al., 1998; Wieser et al., 1995). Using
site-directed mutagenesis, we made similar mutations in
chicken ALK2 and ALK5 and showed that these receptors
were constitutively active (Ward et al., 2002). We then
generated adenoviruses that contained either caALK2 or
caALK5 and GFP expressed by separate CMV promoters.
Adenoviruses were tested for specificity in C3H10T1/2 cells
that produce alkaline phosphatase in response to caALK2 or
high doses of BMP2 (Fujii et al., 1999; Wang et al., 1993).
Cells were infected with adenoviruses containing either
GFP alone, caALK2, or caALK5 and then either vehicle or
1 Ag/ml BMP2 was added. As expected, both BMP2 and
caALK2 stimulated alkaline phosphatase production while
caALK5 did not (Fig. 2A). This indicated that the
Fig. 1. Expression of ALK2 and ALK5 in endocardium. Sections depicted are representative of expression from stage 14 to 19. (A–D) In situ hybridization in
stage 14 chick embryos. Expression of ALK2 (A,B) and ALK5 (C,D) mRNA was compared in adjacent sections. Both ALK2 and ALK5 are expressed
throughout the embryo, but ALK2 is most abundant in endocardial cells (compare B and D). Other endothelial cells, such as those in the dorsal aorta do not
abundantly express ALK2 (B). (E–H) Boundaries of the endocardial expression of ALK2 (Red arrows demarcate the boundaries between high and low
expression). (E,F) ALK2 expression is abundant in AV cushion endocardium, but this high level of expression does not extend into the atria of a stage 18
embryo. (G,H) Expression of ALK2 abruptly decreases in endothelial cells as the OFT exits into the aortic sac of a stage 15 embryo. Panels A–D, G and H are
100 and panels E and F are 40. Reticles in A, C, and G are 100 Am. Reticle in E is 200 Am. V, ventricle; EC, endocardium; DA, dorsal aorta; OT, outflow
tract; A, atria; AVC, atrioventricular cushion.
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for their respective signaling pathways. To further test the
specificity of our viruses, we transfected C3H10T1/2 cells
with the p3TP-lux luciferase reporter plasmid, which is
known to be activated by ALK5 (Bassing et al., 1994; Wieser
et al., 1995). Again, we infected cells with viruses containing
GFP alone, caALK2, or caALK5. As predicted, caALK5
activated the p3TP-lux reporter approximately 5-fold while
caALK2 had a smaller effect (Fig. 2B). The 2-fold
stimulation observed with caALK2 can be explained by
the ability of Smad1, which is activated by caALK2, to
stimulate the p3TP-lux reporter in some cell types (Liu et al.,
1998). These data demonstrate that each adenoviral construct
encodes a constitutively active type I receptor with the
predicted specificity.
Constitutively active ALK2 stimulates EMT in ventricular
explants
To test whether caALK2 or caALK5 are sufficient to
induce EMT, we took advantage of the fact that ventricular
endocardial cells found adjacent to the AV cushion do not
undergo EMT. We used adenoviruses to introduce these
constitutively active receptors into ventricular endocardial
cells and scored for gain of function. In order to infect
endocardial cells prior to the initiation of EMT in the heart,
we injected adenovirus into the lumen of stage 10–12 chickhearts. These stages occur prior to completion of the
circulatory system and before the advent of a regular heart
beat, thus increasing the dwell time in which the endocardial
cells are exposed to the virus. We injected virus into the
heart lumen at these early stages in an effort to efficiently
infect endocardial cells and minimally infect the myocar-
dium. After injection, we allowed the embryos to develop
for 24 h prior to harvesting ventricular explants. The 24-h
incubation period allowed most embryos to reach stage 14–
15, when EMT begins in the AV cushion. Direct observation
of embryos after injection revealed that embryos injected
with any virus used were indistinguishable from uninjected
control embryos. The majority of embryos demonstrate
grossly normal heart and vascular development (Fig. 3A)
and the heart continued to beat and move blood normally.
Imaging of GFP in the intact embryo immediately prior to
harvest showed efficient infection of endocardial cells in the
heart (Fig. 3B). Some embryos were harvested for section-
ing and analysis. No gross abnormalities were noted (Fig.
3C). Ventricular explants were only harvested from grossly
normal embryos that developed to at least stage 14. The
explants were placed on a collagen gel matrix for 48 h,
fixed, and scored for GFP-expressing cells.
We observed a noticeable difference in the phenotype of
explants infected with caALK2 virus compared to those
infected with the GFP control virus. By inspection,
ventricular explants infected with caALK2 adenovirus
Fig. 3. Efficient adenoviral gene delivery to the endocardium. (A)
Photomicrograph of an embryo 24 h following injection. Heart and
vascular development is indistinguishable from similarly treated uninjected
embryos. (B) Immediately prior to explant harvest, imaging of GFP in a
heart injected with adenovirus reveals abundant GFP expression in
endocardial cells. White lines demarcate the position of the myocardium.
(C) A section through the ventricle of a virally infected heart after 24 h of
incubation reveals a lack of gross abnormalities in either the endocardium
or myocardium. Note that virally infected cells, observed by GFP, are
observed only in the endocardium. Paraffin embedding and sectioning was
performed by standard methods (Brown et al., 1999). Representative
photographs are depicted in each case. M, myocardium; EC, endocardium.
Fig. 2. caALK2 and caALK5 activity and specificity. (A) C3H10T1/2 cells
infected with adenovirus encoding GFP alone, caALK2, or caALK5. In the
presence of adenovirus encoding GFP alone, 1 Ag/ml BMP2 stimulates
alkaline phosphatase expression when compared to vehicle. caALK2 also
stimulates expression of alkaline phosphatase, whereas caALK5 does not.
(B) C3H10T1/2 cells transfected with p3TP-lux and infected with
adenovirus encoding GFP alone, caALK2, or caALK5. Compared to
control, caALK5 stimulated luciferase production approximately 5-fold,
whereas caALK2 stimulated the reporter 2-fold. In both (A) and (B) data
are the average of at least 3 assays FSD. Each experiment was performed
three times. Representative experiments are shown (*P b 0.05).
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and small or non-existent epithelial sheets (Fig. 4A). In
contrast, control explants exhibited endocardial cell mono-
layers on the gel surface with few if any elongated, fusiform
cells present (Fig. 4A). To quantify these differences in
phenotype, GFP-expressing cells were scored morphologi-
cally as epithelial, activated, or transformed. We defined
epithelial cells as rounded cells present on the gel surface in
tightly packed sheets. Elongated or fusiform cells present on
the surface of the gel with no cell to cell contacts we
identified as activated. We defined transformed cells as
those elongated cells that invaded the collagen matrix and
thus had completed EMT. By quantifying the number of
GFP-expressing cells in each category, we observed that
caALK2 caused a significant increase in both activated and
transformed cells with a concomitant decrease in the number
of epithelial cells (Fig. 4B). The morphology of caALK5
explants was identical to control explants and no alteration
was noted among any of the cellular phenotypes examined
(Fig. 4C). These data demonstrate that ALK2, but not
ALK5, is sufficient to induce EMT and suggest that native
ALK2 in ventricular endothelial cells is not active in these
normally non-transforming cells.Since caALK5 had no effect in ventricular explants, we
reasoned that caALK5 may have the opposite effect of
caALK2 and negatively regulates EMT. To test this
possibility, we infected AV cushion endothelial cells with
caALK5 adenovirus and again scored GFP-expressing cells.
We found that caALK5 had no effect on the ability of AV
cushion endothelial cells to undergo EMT (Fig. 5A).
Overexpression of caALK2 in AV cushion endothelial cells
results in a significant increase in the percentage of activated
cells (Fig. 5B) which is also the cell phenotype where we
see the most robust change in ventricular explants (Fig. 4B).
Changes in epithelial and transformed cells do not reach
significance (Fig. 5B). This is due to the fact that two
endothelial cell populations are present in the AV cushion,
those fated to transform and those that do not. Here, we are
infecting both cell populations and any effect on the
percentage of epithelial and transformed cells is obscured
by the presence of normally transforming AV cushion
endothelial cells that have been infected with virus. The
complication introduced by the presence of two cell
Fig. 5. Effect of caALK5 and caALK2 on EMT in AV cushion endocardial
cells. AV cushion explants were infected with adenovirus encoding GFP
alone, caALK5, or caALK2. GFP-expressing cells were counted and scored
as epithelial, activated, or transformed and the percent of the total GFP-
expressing cells was calculated. Shown is the average percent of the total
number of GFP-expressing cells for each category, calculated from 3
experiments. caALK5 had no effect on the percent of cells in each category.
GFP: epithelial 50 F 6%; (mean F SD), activated 26 F 0.5%, transformed
23 F 6%. caALK5: epithelial 48 F 13%, activated 28 F 6%, transformed
23 F 7%. Two-tailed Student’s t tests: epithelial P = 0.854, activated P =
0.680, transformed P = 1. caALK2 significantly increased the percentage of
activated cells. GFP: epithelial 40F 2%; (meanF SD), activated 31F 2%,
transformed 29 F 4%. caALK2: epithelial 34 F 4%, activated 38 F 1%,
transformed 28 F 5%. Two-tailed Student’s t tests: epithelial P = 0.161,
activated P = 0.0289, transformed P = 0.840.
Fig. 4. Effect of caALK2 and caALK5 on EMT in ventricular endocardial
cells. (A) Photomicrographs of ventricular explants infected with virus
encoding GFP alone or caALK2. Left panels are bright field images and
right panels are GFP fluorescent images of the same explant. All panels are
at 200 magnification. Arrowheads in the GFP panels identify epithelial
cells while the arrowhead in the caALK2 panel indicates an activated cell.
(B, C) Average percent of total GFP-expressing cells scored as epithelial,
activated, or transformed. Means are derived from 4 separate experiments.
(B) caALK2 induced statistically significant increases in both activated and
transformed cells and a concomitant decrease in epithelial cells. GFP:
epithelial 61 F 12%; (mean F SD), activated 25 F 8%, transformed 14 F
4%. caALK2: epithelial 18 F 2%, activated 57 F 5%, transformed 25 F
4%. Two-tailed Student’s t tests: epithelial P = 0.008, activated P = 0.002,
transformed P = 0.010 (TP b 0.01). (C) caALK5 produced no change in the
percent of cells in each category. GFP: epithelial 61 F 1%, activated 27 F
3%, transformed 12 F 4%. caALK5: epithelial 67 F 9%, activated 23 F
6%, transformed 10 F 3%. Two-tailed Student’s t tests: epithelial P =
0.342, activated P = 0.375, transformed P = 0.498.
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function in the ventricle where a single, normally non-
transforming cell population is found. However, these data
in the AV cushion are consistent with stimulation of ALK2
moving endocardial cells from an epithelial to a mesen-chymal phenotype. Further, the difference in magnitude of
effect of caALK2 on ventricular versus AV cushion
endothelial cells suggests that, although ALK2 is present
in each, ALK2 is not normally active in ventricular
endothelial cells, but is near maximally activated in AV
cushion endothelial cells.
Smad6 overexpression decreases EMT in AV cushion
explants
Smad6 is an inhibitor of Smad signaling downstream of
ALK2, but does not affect ALK5 signaling (Hata et al.,
1998; Macias-Silva et al., 1998). Smad6 is expressed in AV
cushion endocardial cells (Galvin et al., 2000; Yamada et al.,
1999) and targeted deletion of Smad6 results in valvular
hyperplasia that is postulated to be due to enhanced EMT or
cell proliferation (Galvin et al., 2000; Yamada et al., 1999).
To directly test for a role of Smad6 in regulating EMT, we
overexpressed Smad6 in AV cushion endocardial cells. The
Smad6 adenovirus used was previously characterized and
demonstrated to express functional Smad6 protein (McDon-
nell et al., 2001). We injected either Smad6 adenovirus or a
control adenovirus containing lacZ into the lumen of stage
10–12 chick hearts using a titer that infected approximately
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from the infected hearts were cultured for 48 h on collagen
gels before quantifying the total number of cells that
underwent EMT. Our findings show that Smad6 decreased
the number of transformed cells by 35% compared to
control (Fig. 6). These data are consistent with a role for
ALK2 activation in EMT and demonstrate that EMT in the
AV cushion is Smad-dependent.Discussion
TGFh is an important regulator of EMT in the heart, yet
the type I receptor that mediates this effect is unknown. Our
prior studies demonstrated that ALK2 antisera, but not
ALK5 antisera blocked EMT, suggesting a requirement for
ALK2 during transformation (Lai et al., 2000). However,
these studies could not address whether ALK2 was
sufficient to induce EMT, or whether ALK2 mediated its
effects through the endocardium or the myocardium. Here,
we demonstrate that caALK2 is sufficient to stimulate EMT
in the heart and that caALK5 is without effect. These results
show that ALK2 directly stimulates EMT in endocardial
cells. Surprisingly, caALK5 had no effect in ventricular
explants and did not negatively regulate EMT in the AV
cushion. Further, overexpression of Smad6 in AV cushion
endocardial cells decreased EMT, thus supporting a role for
ALK2 and demonstrating that EMT is Smad-dependent.
These data suggest that the effects of TGFh in the heart are
independent of the prototypical type I TGFh receptor
ALK5, and instead, are mediated by ALK2 signaling
through Smads.
We propose that ALK2 may signal EMT in response to
TGFh ligands based on experiments in which exogenous
TGFh supported both activation and transformation in AV
cushion endocardial cells (Potts and Runyan, 1989; Potts et
al., 1991). Besides TGFh, ALK2 also binds BMPs and
activins, though only binding of BMP7 to ALK2 has been
demonstrated to result in activation of ALK2 kinase activityFig. 6. Overexpression of Smad6 decreases EMT in the AV cushion.
Adenovirus containing either the lacZ or Smad6 transgene was used to
infect AV cushion explants. Total transformed cells were scored for each
explant and expressed as a percentage of the mean number of cells found in
control explants F SEM. Comparison of lacZ and Smad6 data by a two-
tailed Student’s t test is significant (TP b 1  105).(Macias-Silva et al., 1998). In the mouse, BMP7 is
expressed throughout the myocardium (Dudley and Rob-
ertson, 1997; Solloway and Robertson, 1999) and at E12.5
is found in mesenchyme under the valve leaflets (Kim et al.,
2001). However, mice with a targeted deletion of Bmp7 lack
cardiac defects (Dudley et al., 1995; Luo et al., 1995). We
found that addition of BMP7 to ventricular explants had no
effect on EMT despite the presence of ALK2 (data not
shown). This raises the question of whether and how ALK2
is activated in ventricular endothelial cells during cardiac
development.
There is emerging evidence that TGFh signaling
diversity may be associated with the differential coupling
of TGFh to type I receptors other than ALK5. ALK1, the
molecule most closely related to ALK2, was discovered to
mediate TGFh-dependent responses during angiogenesis.
Experiments in endothelial cells demonstrated that low
concentrations of TGFh act via ALK1 to stimulate the
endothelial cell migration and proliferation required for
angiogenesis (Goumans et al., 2002). Our laboratory is
asking whether ALK2, like ALK1, mediates TGFh-depend-
ent responses. We identified a role for ALK2 downstream of
TGFh during development of the parasympathetic response
in chick atrial myocytes (Ward et al., 2002). Constitutively
active ALK2 was found to reproduce the effects of TGFh on
Gai2 expression in 14 day in ovo (dio) atrial myocytes. In
these same cells, TGFh stimulated the ALK5-unresponsive,
ALK2-responsive pVent luciferase reporter. In the present
study, we demonstrate that ALK2 is sufficient to stimulate a
TGFh-dependent EMT in the AV cushion whereas we have
been unable to identify a role for ALK5. These data support
the hypothesis that ALK2 may mediate TGFh signaling.
The differential expression of ALK2 may represent a
mechanism for specifying cellular responsiveness to TGFh.
We observed abundant expression of ALK2 mRNA in
endocardial cells of the OFT, ventricle, and AV cushion, but
not in extra-cardiac endothelial cells. Differential expression
of ALK1 has also been noted in endothelial cells. ALK1
levels were observed to be significantly higher in the
endothelium of arterioles compared with venous endothelial
cells (Goumans et al., 2002). It is tempting to speculate that
the localized expression of high levels of ALK2 mRNA in
the endocardium of the developing heart affects coupling of
TGFh signals to ALK2 instead of ALK5. Our examination
of the development of the parasympathetic response in atrial
myocytes demonstrated that TGFh activation of the pVent-
luc reporter correlated with an increase in ALK2 expression.
Increased levels of ALK2 compared to ALK5 caused TGFh
signaling to apparently switch from ALK5 in 5 dio atrial
myocytes to ALK2 in 14 dio cells. This suggests that the
stoichiometry between ALK2 and ALK5 may determine
which type I receptor mediates the effects of TGFh in a
given cell.
Other TGFh receptors may also influence which type I
receptor is recruited to the signaling complex. Prior studies
in our laboratory demonstrated that neutralizing antisera
J.S. Desgrosellier et al. / Developmental Biology 280 (2005) 201–210208against TBRII or TBRIII blocked endocardial cell activation
and subsequent transformation in the AV cushion (Brown et
al., 1996, 1999). Further, misexpression of TBRIII in the
ventricle and addition of TGFh2 results in EMT in non-
transforming ventricular endocardial cells (Brown et al.,
1999). Demonstration of a requirement for TBRII and
TBRIII during EMT, and co-localization of these receptors
in AV cushion endothelial cells, led us to propose that a
complex of at least TBRII and TBRIII mediates EMT in the
AV cushion. The current model of TGFh signal transduction
presupposes that a type I receptor is an essential component
of the signal transduction complex. Data presented here, and
prior studies using neutralizing antisera to ALK2 and ALK5
(Lai et al., 2000), suggest that ALK2 is the type I receptor
required for EMT in the AV cushion and not ALK5. Based
on these results, we suggest that a complex of ALK2,
TBRII, and TBRIII mediates EMT in the AV cushion in
response to TGFh ligands. TBRIII is expressed in endothe-
lial cells lining the AVand OFT cushions which are a subset
of endothelial cells that abundantly express ALK2. This
overlapping expression of TBRIII and ALK2 may be
required for ALK2 activation and may explain why AV
endothelial cells undergo EMT and ventricular endothelial
cells do not. A precedent for an interaction between TBRIII
and ALK2 exists with regards to the two most related
molecules, endoglin and ALK1, respectively. The demon-
stration that mutations in either endoglin (McAllister et al.,
1994) or ALK1 (Johnson et al., 1996) result in hereditary
hemorrhagic telangiectasia provides genetic evidence that
endoglin and ALK1 lie in the same or parallel pathways to
regulate blood vessel morphology. Lux et al. (1999)
demonstrated a direct association of ALK1 with endoglin
and that TGFh addition activated ALK1 signaling. These
data suggest that endoglin modulates TGFh signaling by
activating type I receptors other than ALK5. We hypothe-
size a similar role for TBRIII, which may influence
downstream signaling by recruiting ALK2 to the signaling
complex instead of ALK5.
Smad6 may function as an endogenous regulator of EMT
in the heart. In support of this, Smad6 mRNA is expressed
in the developing heart during EMT and is especially
abundant in the OFT and AV cushion in both chick and
mouse (Galvin et al., 2000; Yamada et al., 1999). Further,
mice homozygous null for Madh6 (which encodes the
Smad6 protein) develop valvular hyperplasia that the
authors propose may be caused by enhanced EMT or
mesenchymal cell proliferation in the endocardial cushions
(Galvin et al., 2000). Our experiments tested the effects of
Smad6 on EMT directly. We found that overexpression of
Smad6 decreased EMT in the AV cushion, supporting a role
for Smad6 as a negative regulator of EMT. We have
demonstrated here that ALK2 is sufficient to induce EMT.
Work from other laboratories has shown that Smad1, 5, and
8 are downstream of ALK2, whereas ALK5 signals through
Smad2 and 3 (Chen and Massague, 1999; Chen et al., 1997;
Macias-Silva et al., 1998; Nakao et al., 1997). Since Smad6is a selective antagonist of Smad1 signaling (Hata et al.,
1998), it would be expected to inhibit ALK2 signaling
through Smads. Although we cannot exclude the possibility
that ALK2 and Smad6 are in parallel pathways that regulate
EMT, we propose that Smad6 negatively regulates EMT by
inhibiting ALK2 signaling. Therefore, Smad6 may act
endogenously to regulate the number of cells that undergo
EMT, and thereby regulate valvulogenesis, by inhibiting
Smad signaling downstream of ALK2.
ALK2 and Smad6 regulation of EMT during valvulo-
genesis implicates these two molecules in congenital heart
disease. Occurring at a rate of nearly 1 in 100 live births,
congenital heart disease is a common problem that often
includes valve malformations (Hoffman, 1990; Hoffman
and Kaplan, 2002). Outside of the heart, EMT is an
important process throughout development and tumor
progression. The determination of other examples of EMT
that involve ALK2 and Smad6, and the identification of
factors that favor ALK2 over ALK5 signaling, are likely to
yield novel insight into the causes of congenital defects and
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